2026-04-29T19:35:03Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/180902024-11-28T15:00:08Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927

00925njm 22002777a 4500 dc García-Argüello, Segundo Francisco author Lopez-Lorenzo, Beatriz author Cornelissen, Bart author Smith, Graham author 2020-08-06 Insufficient apoptosis is a recognised hallmark of cancer. A strategy to quantitatively measure apoptosis in vivo would be of immense value in both drug discovery and routine patient management. The first irreversible step in the apoptosis cascade is activation of the "executioner" caspase-3 enzyme to commence cleavage of key structural proteins. One strategy to measure caspase-3 activity is Positron Emission Tomography using isatin-5-sulfonamide radiotracers. One such radiotracer is [18F]ICMT-11, which has progressed to clinical application. This review summarises the design and development process for [18F]ICMT-11, suggesting potential avenues for further innovation. 10.3390/cancers12082191 2072-6694 Cancers http://hdl.handle.net/10668/4148 32781531 http://hdl.handle.net/20.500.12105/18090 Positron emission tomography Apoptosis Caspase-3 [18F]ICMT-11 Pyrimidoindolone Michael acceptor Neoplasms Isatin Tomografía de emisión de positrones Caspasa-3 Neoplasias Isatina Development of [18F]ICMT-11 for Imaging Caspase-3/7 Activity during Therapy-Induced Apoptosis